Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Acura Pharmaceuticals, Inc. stock logo
ACUR
Acura Pharmaceuticals
$0.01
$0.00
$0.00
$0.05
$663K1.892,949 shsN/A
Earth Science Tech, Inc. stock logo
ETST
Earth Science Tech
$0.06
$0.07
$0.00
$0.12
$18.29M1.7796,756 shs138,416 shs
iCo Therapeutics Inc. stock logo
ICOTF
iCo Therapeutics
$0.34
$0.37
$0.80
$1.82
$3.09M2.034,760 shsN/A
Kaya Holdings, Inc. stock logo
KAYS
Kaya
$0.04
+34.5%
$0.04
$0.03
$0.09
$574K0.585,010 shs30,880 shs
Neurotrope, Inc. stock logo
NTRP
Neurotrope
$2.76
-7.1%
$0.96
$0.68
$3.85
$2.15M1.5410,072 shs1,238 shs
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Acura Pharmaceuticals, Inc. stock logo
ACUR
Acura Pharmaceuticals
0.00%+257.14%+185.71%+733.33%-80.00%
Earth Science Tech, Inc. stock logo
ETST
Earth Science Tech
-13.24%-9.23%-11.94%-1.67%+84.38%
iCo Therapeutics Inc. stock logo
ICOTF
iCo Therapeutics
-5.31%-7.92%-5.36%-13.49%-33.84%
Kaya Holdings, Inc. stock logo
KAYS
Kaya
+4.29%-5.81%-18.89%-32.87%-46.52%
Neurotrope, Inc. stock logo
NTRP
Neurotrope
+3.85%-8.05%-30.77%+215.62%+215.62%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Acura Pharmaceuticals, Inc. stock logo
ACUR
Acura Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Earth Science Tech, Inc. stock logo
ETST
Earth Science Tech
N/AN/AN/AN/AN/AN/AN/AN/A
iCo Therapeutics Inc. stock logo
ICOTF
iCo Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Kaya Holdings, Inc. stock logo
KAYS
Kaya
N/AN/AN/AN/AN/AN/AN/AN/A
Neurotrope, Inc. stock logo
NTRP
Neurotrope
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Acura Pharmaceuticals, Inc. stock logo
ACUR
Acura Pharmaceuticals
N/AN/AN/AN/A
Earth Science Tech, Inc. stock logo
ETST
Earth Science Tech
N/AN/AN/AN/A
iCo Therapeutics Inc. stock logo
ICOTF
iCo Therapeutics
N/AN/AN/AN/A
Kaya Holdings, Inc. stock logo
KAYS
Kaya
N/AN/AN/AN/A
Neurotrope, Inc. stock logo
NTRP
Neurotrope
N/AN/AN/AN/A

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Acura Pharmaceuticals, Inc. stock logo
ACUR
Acura Pharmaceuticals
$1.56M0.43N/AN/AN/A
Earth Science Tech, Inc. stock logo
ETST
Earth Science Tech
$50K365.78N/AN/AN/A
iCo Therapeutics Inc. stock logo
ICOTF
iCo Therapeutics
N/AN/AN/AN/A($0.07) per shareN/A
Kaya Holdings, Inc. stock logo
KAYS
Kaya
$200K2.87$0.18 per share0.22($1.07) per share-0.04
Neurotrope, Inc. stock logo
NTRP
Neurotrope
$630K3.42N/AN/A$9.67 per share0.29

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Acura Pharmaceuticals, Inc. stock logo
ACUR
Acura Pharmaceuticals
-$880KN/A0.00N/AN/AN/AN/AN/A
Earth Science Tech, Inc. stock logo
ETST
Earth Science Tech
-$370KN/A0.00N/A5.77%20.61%11.73%N/A
iCo Therapeutics Inc. stock logo
ICOTF
iCo Therapeutics
-$1.11M-$0.40N/AN/AN/AN/A-288.85%N/A
Kaya Holdings, Inc. stock logo
KAYS
Kaya
$1.61M-$0.02N/AN/A821.43%-9.57%638.26%4/26/2024 (Estimated)
Neurotrope, Inc. stock logo
NTRP
Neurotrope
-$8.69M-$10.97N/AN/A-1,123.90%-180.93%-148.77%5/20/2024 (Estimated)

Latest NTRP, KAYS, ICOTF, ETST, and ACUR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/16/2024Q4 2023
Kaya Holdings, Inc. stock logo
KAYS
Kaya
N/A$0.01+$0.01$0.01N/A$0.03 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Acura Pharmaceuticals, Inc. stock logo
ACUR
Acura Pharmaceuticals
N/AN/AN/AN/AN/A
Earth Science Tech, Inc. stock logo
ETST
Earth Science Tech
N/AN/AN/AN/AN/A
iCo Therapeutics Inc. stock logo
ICOTF
iCo Therapeutics
N/AN/AN/AN/AN/A
Kaya Holdings, Inc. stock logo
KAYS
Kaya
N/AN/AN/AN/AN/A
Neurotrope, Inc. stock logo
NTRP
Neurotrope
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Acura Pharmaceuticals, Inc. stock logo
ACUR
Acura Pharmaceuticals
N/AN/AN/A
Earth Science Tech, Inc. stock logo
ETST
Earth Science Tech
0.10
0.87
0.39
iCo Therapeutics Inc. stock logo
ICOTF
iCo Therapeutics
N/A
0.72
0.72
Kaya Holdings, Inc. stock logo
KAYS
Kaya
N/A
0.01
0.01
Neurotrope, Inc. stock logo
NTRP
Neurotrope
N/A
1.65
0.76

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Acura Pharmaceuticals, Inc. stock logo
ACUR
Acura Pharmaceuticals
N/A
Earth Science Tech, Inc. stock logo
ETST
Earth Science Tech
N/A
iCo Therapeutics Inc. stock logo
ICOTF
iCo Therapeutics
N/A
Kaya Holdings, Inc. stock logo
KAYS
Kaya
N/A
Neurotrope, Inc. stock logo
NTRP
Neurotrope
3.81%

Insider Ownership

CompanyInsider Ownership
Acura Pharmaceuticals, Inc. stock logo
ACUR
Acura Pharmaceuticals
20.20%
Earth Science Tech, Inc. stock logo
ETST
Earth Science Tech
24.90%
iCo Therapeutics Inc. stock logo
ICOTF
iCo Therapeutics
N/A
Kaya Holdings, Inc. stock logo
KAYS
Kaya
23.52%
Neurotrope, Inc. stock logo
NTRP
Neurotrope
9.70%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Acura Pharmaceuticals, Inc. stock logo
ACUR
Acura Pharmaceuticals
966.35 million52.95 millionNot Optionable
Earth Science Tech, Inc. stock logo
ETST
Earth Science Tech
8309.98 million232.80 millionNot Optionable
iCo Therapeutics Inc. stock logo
ICOTF
iCo Therapeutics
N/A9.05 millionN/ANot Optionable
Kaya Holdings, Inc. stock logo
KAYS
Kaya
414.72 million11.26 millionNot Optionable
Neurotrope, Inc. stock logo
NTRP
Neurotrope
5780,000704,000No Data

NTRP, KAYS, ICOTF, ETST, and ACUR Headlines

SourceHeadline
NextTrip Inc NTRPNextTrip Inc NTRP
morningstar.com - April 4 at 9:52 PM
NextTrip Engages MZ Group to Lead Strategic Investor Relations and Shareholder Communications ProgramNextTrip Engages MZ Group to Lead Strategic Investor Relations and Shareholder Communications Program
accesswire.com - April 2 at 9:01 AM
Racquet Review: Donnay X-Red 99Racquet Review: Donnay X-Red 99
tennis.com - September 26 at 3:04 PM
Alzheimers Disease Market Predicted to Surge at a CAGR of 20% During the Study Period (2019–2032), Assesses DelveInsightAlzheimer's Disease Market Predicted to Surge at a CAGR of 20% During the Study Period (2019–2032), Assesses DelveInsight
finance.yahoo.com - August 17 at 5:10 PM
Game, Set, Match: KJF Gears Up for Tennis ShowdownGame, Set, Match: KJF Gears Up for Tennis Showdown
patch.com - August 2 at 5:25 AM
Racquet Reviews: Yonex RDiS 200 HG/RDiS 200 GRacquet Reviews: Yonex RDiS 200 HG/RDiS 200 G
tennis.com - June 23 at 3:40 PM
Even Rod Laver has one that got away: 1972 WCT Finals loss to RosewallEven Rod Laver has one that got away: 1972 WCT Finals loss to Rosewall
tennis.com - June 10 at 6:18 PM
Racquet Review: Volkl Organix 4Racquet Review: Volkl Organix 4
tennis.com - May 28 at 7:20 PM
Racquet Review: Wilson Six.One 95 BLX 16x18Racquet Review: Wilson Six.One 95 BLX 16x18
tennis.com - May 26 at 4:25 PM
The Cholinergic System in the Pathophysiology and Treatment of Alzheimers DiseaseThe Cholinergic System in the Pathophysiology and Treatment of Alzheimer's Disease
medscape.com - May 19 at 8:13 PM
Racquet Review: Pacific X Force ProRacquet Review: Pacific X Force Pro
tennis.com - May 8 at 8:38 PM
Review: Wilson Khamsin Five BLX 108Review: Wilson Khamsin Five BLX 108
tennis.com - May 7 at 6:11 PM
Alzheimers Disease Pipeline Assessment (2023 Updates) | In-depth Insights into the Clinical Trials, Emerging - openPRAlzheimer's Disease Pipeline Assessment (2023 Updates) | In-depth Insights into the Clinical Trials, Emerging - openPR
news.google.com - April 12 at 2:58 PM
Racquet Review: Prince EXO3 White Lite 100Racquet Review: Prince EXO3 White Lite 100
tennis.com - April 5 at 8:49 PM
Fragile X Syndrome Emerging and Marketed Drugs Assessment (2023 Updates) | Clinical and Non-Clinical Trials Ev - openPRFragile X Syndrome Emerging and Marketed Drugs Assessment (2023 Updates) | Clinical and Non-Clinical Trials Ev - openPR
news.google.com - March 23 at 1:08 PM
DelveInsight Evaluates a Robust Alzheimers Disease Pipeline as 150+ Influential Pharma Players to Set Foot in the Domain - Yahoo FinanceDelveInsight Evaluates a Robust Alzheimer's Disease Pipeline as 150+ Influential Pharma Players to Set Foot in the Domain - Yahoo Finance
news.google.com - February 28 at 10:20 AM
Alzheimers Disease Market to observe Growth during 2022-2032 ... - Digital JournalAlzheimer's Disease Market to observe Growth during 2022-2032 ... - Digital Journal
news.google.com - February 28 at 5:19 AM
DelveInsight Evaluates a Robust Alzheimers Disease Pipeline as ... - PR NewswireDelveInsight Evaluates a Robust Alzheimer's Disease Pipeline as ... - PR Newswire
news.google.com - February 27 at 12:26 PM
Neurology Devices Market Demand Volume Share Overview ... - Digital JournalNeurology Devices Market Demand Volume Share Overview ... - Digital Journal
news.google.com - February 23 at 10:10 PM
World Alzheimers Disease Therapeutics Analysis Report 2022: A ... - InvestorsObserverWorld Alzheimer's Disease Therapeutics Analysis Report 2022: A ... - InvestorsObserver
news.google.com - February 15 at 8:27 AM
Alzheimers Disease Pipeline Appears Robust With 100+ Key ... - Digital JournalAlzheimer's Disease Pipeline Appears Robust With 100+ Key ... - Digital Journal
news.google.com - January 26 at 12:39 AM
Alzheimers Disease Therapeutics Market Report Research 2022 ... - PR NewswireAlzheimer's Disease Therapeutics Market Report Research 2022 ... - PR Newswire
news.google.com - January 20 at 6:49 PM
World Alzheimers Disease Therapeutics Analysis Report 2022: 101 ... - Galveston County Daily NewsWorld Alzheimer's Disease Therapeutics Analysis Report 2022: 101 ... - Galveston County Daily News
news.google.com - December 20 at 5:33 PM
Alzheimers Disease Market to Observe Growth by (2022-2032 ... - Digital JournalAlzheimer's Disease Market to Observe Growth by (2022-2032 ... - Digital Journal
news.google.com - December 20 at 7:31 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Acura Pharmaceuticals logo

Acura Pharmaceuticals

OTCMKTS:ACUR
Acura Pharmaceuticals, Inc., an innovative drug delivery company, engages in the research, development, and commercialization of technologies and products to address safe use of medications in the United States. It offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed products, which are pseudoephedrine and acetaminophen tablets that are used as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy products. Acura Pharmaceuticals, Inc. has collaboration and license agreements with Egalet US, Inc. and Egalet Ltd. to manufacture and commercialize Oxaydo products worldwide; and development and commercialization agreement with Abuse Deterrent Pharma, LLC to develop LTX-03, an immediate-release tablets utilizing LIMITx technology. The company was formerly known as Halsey Drug Co., Inc. The company was incorporated in 1935 and is based in Palatine, Illinois. Acura Pharmaceuticals, Inc. operates as a subsidiary of Abuse Deterrent Pharma, LLC.
Earth Science Tech logo

Earth Science Tech

OTCMKTS:ETST
Earth Science Tech, Inc. focuses on health and wellness industry. It operates men's health telemedicine platform under brand Peak name; and operates pharmacy. The company offers supplements and topicals products. The company was formerly known as Ultimate Novelty Sports, Inc. and changed its name to Earth Science Tech, Inc. in March 2014. Earth Science Tech, Inc. was incorporated in 2010 and is headquartered in Miami, Florida.
iCo Therapeutics logo

iCo Therapeutics

OTCMKTS:ICOTF
Satellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics. It operates through a proprietary technology platform, MyoReGenX™ and Leveraging MyoReGenX™, which identify stem cell based regeneration deficits in muscle diseases and develop therapeutic solutions. The company was founded by Frank Gleeson and Michael Rudnicki in 2018 and is headquartered in Toronto, Canada.
Kaya logo

Kaya

OTCMKTS:KAYS
Kaya Holdings, Inc., a vertically integrated legal cannabis enterprise, produces, distributes, and/or sells a range of cannabis products primarily in the United States. The company offers flower, oils, vape cartridges and cannabis infused confections, baked goods, and beverages. It also operates retail outlets under the Kaya Shack brand name, as well as offers strain specific cannabis cigarettes under the Kaya Buddies name, and strains of cannabis under the Kaya Farms name. In addition, the company provides standing display cases with cannabis intended glassware under the Really Happy Glass brand; and t-shirt designs under the Kaya Gear brand name. The company was formerly known as Alternative Fuels America, Inc. and changed its name to Kaya Holdings, Inc. in April 2015. Kaya Holdings, Inc. was incorporated in 1993 and is headquartered in Fort Lauderdale, Florida.
Neurotrope logo

Neurotrope

NASDAQ:NTRP
Neurotrope, Inc., a biopharmaceutical company, focuses on the development of a product platform for the treatment of Alzheimer's disease. The company's lead product candidate is bryostatin, a natural product isolated from a marine invertebrate organism, a bryozoan called Bugula neritina. It also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, multiple sclerosis, and niemann-pick type C diseases. The company has a license agreement with The Board of Trustees of the Leland Stanford Junior University for the use of bryostatin structural derivatives, known as bryologs, for use in the treatment of central nervous system disorders, lysosomal storage diseases, stroke, cardio protection, and traumatic brain injury; and a license agreement to an accelerated synthesis of bryostatin-1. Neurotrope, Inc. also has a cooperative research and development agreement with the National Cancer Institute for the research and clinical development of Bryostatin-1. The company was founded in 2012 and is based in New York, New York.